Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 3Sarcoma 1Other solid neoplasm 1Gynecologic 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Osteosarcoma 1

Interventions

Doxorubicin 5Cyclophosphamide 4anlotinib 3Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Neoadjuvant Therapy 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1spartalizumab 1relmacabtagene autoleucel 1regorafenib 1penpulimab 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × irinotecan sucrosofate × Sarcoma × Clear all
NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
33 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡